Non-Small Cell Lung Cancer, Lung Cancer, Cancer
Conditions
Brief summary
The purpose of this observational study is to describe patient and disease characteristics as well as treatment patterns in Chinese patients with unresectable stage IIIB or IV non-small cell lung cancer (NSCLC). In addition, this study characterizes the clinical outcomes for various populations of patients defined by clinical and tumor characteristics, treatment patterns, and hospital category defined by city tier and geographic region.
Interventions
OTHERNo intervention
No intervention administered in this study
Sponsors
Hoffmann-La Roche
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Histologically/cytologically confirmed, unresectable Stage IIIB or IV non-small cell lung cancer (NSCLC) * Received at least one anti-cancer treatment targeting unresectable Stage IIIB or IV NSCLC in the study site after study initiation * Radiographic evidence of disease
Exclusion criteria
* Prior systematic treatment for unresectable Stage IIIB or IV non-small cell lung cancer (NSCLC) * Participation in any anti-cancer, regimen-specified clinical study of first-line treatment for unresectable Stage IIIB or IV NSCLC.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival (OS) | From enrollment to end of study up to 1.5 years |
| Score Tumor Characteristics Based on Tumor Histology, Stage, Grade, and Lung Cancer Molecular Profile | At enrollment, during quarterly and semi-annual follow up and at end of study up to 1.5 years |
| Grade of Eastern Cooperative Oncology Group (ECOG) Performance Status | At enrollment, during quarterly and semi-annual follow up and at end of study up to 1.5 years |
| Treatment Patterns of First-Line and Subsequent Treatments | At enrollment, during quarterly and semi-annual follow up and at end of study up to 1.5 years |
| Progression-Free Survival (PFS) | From enrollment to end of study up to 1.5 years |
| Demographic and Socio-Behavioral Characteristics | At enrollment |
| Medical History Characteristics | At enrollment |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of Serious Adverse Events (SAEs) | From enrollment to end of study up to 1.5 years |
| Percentage of Adverse Events (AEs) | From enrollment to end of study up to 1.5 years |
| Percentage of Non-Serious AEs of Special Interest (AESIs) | From enrollment to end of study up to 1.5 years |
| Score Health Economic Status Based on Household Income, Diagnosis and Treatment Costs, and Insurance Coverage | At enrollment, during quarterly and semi-annual follow up and at end of study up to 1.5 years |
Countries
China
Outcome results
None listed